发明名称 Camptothecin-binding moiety conjugates
摘要 The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.
申请公布号 US8834886(B2) 申请公布日期 2014.09.16
申请号 US201314078941 申请日期 2013.11.13
申请人 Immunomedics, Inc. 发明人 Govindan Serengulam V.;Goldenberg David M.;Moon Sung-Ju
分类号 A61K39/00;A61K47/48;A61K45/06;C07K16/28;C07K16/10;C07K16/30 主分类号 A61K39/00
代理机构 代理人 Nakashima Richard A.
主权项 1. A method comprising administering to a subject, wherein the subject has an infection or an infectious lesion, an immunoconjugate comprising: (a) an antibody or antigen-binding antibody fragment that targets an antigen or epitope or iron-siderophore chelate receptor on a pathogen associated with said infection or infectious lesion; (b) a chemotherapeutic moiety; and (c) a linker comprising (i) a thiol-reactive functional group that binds to a thiol group on the antibody, and (ii) a water-solubilizing moiety selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), triethylenetetraminehexaacetic acid (TTHA), benzyl-DTPA, 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA), benzyl-DOTA, 1,4,7-triazacyclononane-N,N′,N″-triacetic acid (NOTA), benzyl-NOTA, 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA) and N,N′-dialkyl substituted piperazine,wherein the chemotherapeutic moiety is attached to the linker via an intracellularly-cleavable moiety that is cleavable by intracellular esterases and comprises an ester formed from the α-carboxylic acid of an amino acid, and said thiol-reactive functional group is a maleimide or vinylsulfone which links to thiol groups of said antibody.
地址 Morris Plains NJ US